Sangamo buys stake in French firm developing cell therapies for autoimmune disease
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.
organ transplant rejection
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.